Postjunctional α2C-adrenoceptor contractility in human saphenous vein
Charles A Rizzo,Lori M Ruck,Michel R Corboz,Shelby P Umland,Yuntao Wan,Himanshu Shah,James Jakway,Lihong Cheng,Kevin McCormick,Robert W Egan,John A Hey
DOI: https://doi.org/10.1016/S0014-2999(01)00772-5
IF: 5.195
2001-01-01
European Journal of Pharmacology
Abstract:The postjunctional α2-adrenoceptor-mediated contractility was characterized in human saphenous vein derived from coronary artery bypass graft surgery. Human saphenous vein contracted to α2-adrenoceptor selective agonists BHT-920 (5,6,7,8-Tetrahydro-6-(2-propenyl)-4H-thiazolo[4,5-d]azepin-2-amine dihydrochloride; pD2=6.7±0.1) and UK 14,304 (5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; pD2=7.2±0.1). BHT-920-induced contractions were inhibited by the α2-adrenoceptor antagonist yohimbine (17-Hydroxy-yohimban-16-carboxylic acid methyl ester hydrochloride; pA2=8.7±0.5), but not by the α1-adrenoceptor antagonist prazosin (1-[4-Amino-6,7-dimethoxy-2-quinazolinyl]-4-[2-furanylcarbonyl]-piperazine hydrochloride; 300 nM). In contrast, prazosin (pKb=7.9±0.2) potently antagonized contractions elicited by the α1-adrenoceptor agonist phenylephrine ((R)-3-Hydroxy-α-[(methylamino)methyl] benzenemethanol hydrochloride; pD2=4.9±0.1), indicating that both α2- and α1-adrenoceptor evoke human saphenous vein contractions. Functional antagonist activity estimates (pA2 or pKb) obtained for the α-adrenoceptor antagonists ARC 239 (2-[2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl]-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione dihydrochloride), WB 4101 (2-(2,6-Dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane hydrochloride) and HV 723 (α-ethyl-3,4,5-trimethoxy-α-(3-((2-(2-methoxyphenoxy) ethyl)amino)propyl)benzeneacetonitrile) against BHT-920-induced human saphenous vein contractions were 7.0±0.6, 8.3±0.6 and 7.7±0.3, respectively. The α2-adrenoceptor subtype affinities (pKi) obtained in recombinant human α2A-, α2B- and α2C-adrenoceptor competition binding assays were 8.6, 8.3 and 8.6 for yohimbine; 6.3, 8.4 and 7.0 for ARC 239; 8.4, 7.5 and 8.4 for WB 4101 and 7.5, 7.4 and 7.9 for HV 723, respectively. Taken together, the binding and functional antagonist activity estimates obtained in these investigations indicate that α2C-adrenoceptor is the predominant postjunctional α2-adrenoceptor subtype in human saphenous vein.